Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing
Published: September 19, 2019
- Many lifesaving oncology drugs may adversely affect the cardiovascular (CV) system, causing irreversible cardiac injury and reduced quality of life.
- The emergence of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) as an in vitro research tool holds great promise for understanding drug-induced cardiotoxicity.
- This statement reviews the challenges of cardio-oncology, strengths and limitations of using hiPSC-CMs to represent clinical findings in the non-clinical research space, and future directions for their further use.
- Cardio-Oncology: Vascular and Metabolic Perspectives
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect
- Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine
- Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine
- The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction
- Future Translational Applications from the Contemporary Genomics Era
- Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy